synthetic heptapeptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-08-21. Anything still debated is marked as such rather than presented as settled.
Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Seven-residue peptide |
| Molecular mass | 813.9 Da | Monoisotopic value |
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Freely soluble in water | Also soluble in saline and polar solvents |
| Storage (dry) | -20 °C or lower | Desiccated, protected from light |
各国监管态度分化明显。俄罗斯按处方药管理，部分东欧国家留有使用记录；欧盟与美国未批准其作为药物上市，市面流通品通常标注为研究用化学品。身份差异意味着标示含量、纯度与无菌性缺少统一核查。体育领域还牵涉反兴奋剂名录，跨境携带则受目的地药品法规约束。
Semax 是人工设计的七肽，序列为 Met-Glu-His-Phe-Pro-Gly-Pro，骨架取自促肾上腺皮质激素片段 ACTH(4-10)。它于二十世纪八十年代在苏联的分子遗传学研究机构内合成。设计目标是保留该片段与注意力和记忆相关的活性，同时剔除促皮质激素释放等内分泌作用。此后俄罗斯将其登记为药品并进入临床使用。
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
To simplify this process, genetic engineering is often used to add chemical features to proteins that make them easier to purify without affecting their structure or activity. Here, a "tag" consisting of a specific amino acid sequence, often a series of histidine residues (a "His-tag"), is attached to one terminus of the protein. As a result, when the lysate is passed over a chromatography column containing nickel, the histidine residues ligate the nickel and attach to the column while the untagged components of the lysate pass unimpeded. A number of tags have been developed to help researchers purify specific proteins from complex mixtures.
α2β1-mediated collagen binding also stimulates outside-in signaling, which plays a role in platelet spreading and cytoskeletal remodeling, thus increasing the surface area of the activated platelets and providing a way for interaction between them and neighboring platelets and coagulation factors. This process helps in the stabilization of the forming clot. Though α2β1 receptor on its own cannot activate the platelets completely, it cooperates with other platelet receptors such as GPVI, to form a thrombus after vascular injury. The α2β1 integrin facilitates primary hemostasis through platelet adhesion to collagen exposed after injury to the Endothelial cells of blood vessels. In healthy vessels, collagen is found underneath the endothelial cells and is not accessible to platelets flowing through the blood vessels. After wounding, the collagen is exposed and enables the platelet receptors for collagen, such as α2β1 integrin and GPVI, to adhere to the wound surface and begin the formation of a hemostatic plug. Unlike GPVI, that is mainly responsible for signal transduction, α2β1 integrin is predominantly responsible for increasing platelet adhesion to collagen and stabilizing platelet attachment to the site of injury. Stable engagement becomes especially relevant in situations involving high shear stress in the arterial system because the force of the flowing blood might disrupt the attachment of platelets.
GameSpy hailed Natural Selection as "possibly the most ambitious user-made modification ever brought to fruition. This multiplayer-only mod somehow manages to transform the aging Half-Life into a seemingly brand-new, atmospheric, and surprisingly deep action-strategy game, pitting hive-minded aliens against resourceful space marines," and "Natural Selection's innovations are too numerous to list, but the marine's "commander" mode deserves special mention. Playing as the marine commander, you can order and re-supply other marines in an RTS-style, top-down perspective." FiringSquad : "The way all these details boil down in gameplay is simply amazing, and occasionally fascinating to just watch unfold," and "is probably one of the most creative and well thought out shooters we’ve played in a very long time."
A drug carrier or drug vehicle is a substrate used in the process of drug delivery which serves to improve the selectivity, effectiveness, and/or safety of drug administration. Drug carriers are primarily used to control the release of drugs into systemic circulation. This can be accomplished either by slow release of a particular drug over a long period of time (typically diffusion) or by triggered release at the drug's target by some stimulus, such as changes in pH, application of heat, and activation by light. Drug carriers are also used to improve the pharmacokinetic properties, specifically the bioavailability, of many drugs with poor water solubility and/or membrane permeability. A wide variety of drug carrier systems have been developed and studied, each of which has unique advantages and disadvantages. Some of the more popular types of drug carriers include liposomes, polymeric micelles, microspheres, and nanoparticles. Different methods of attaching the drug to the carrier have been implemented, including adsorption, integration into the bulk structure, encapsulation, and covalent bonding. Different types of drug carrier utilize different methods of attachment, and some carriers can even implement a variety of attachment methods.
Sources: en.wikipedia.org
Twenty chemical elements are known to be required to support human biochemical processes by serving structural and functional roles, and there is evidence for a few more. Oxygen, hydrogen, carbon and nitrogen are the most abundant elements in the body by weight and make up about 96% of the weight of a human body. Calcium makes up 920 to 1200 grams of adult body weight, with 99% of it contained in bones and teeth. This is about 1.5% of body weight. Phosphorus occurs in amounts of about 2/3 of calcium, and makes up about 1% of a person's body weight. The other major minerals (potassium, sodium, chlorine, sulfur and magnesium) make up only about 0.85% of the weight of the body. Together these eleven chemical elements (H, C, N, O, Ca, P, K, Na, Cl, S, Mg) make up 99.85% of the body. The remaining ≈18 ultratrace minerals comprise just 0.15% of the body, or about one hundred grams in total for the average person. Total fractions in this paragraph are amounts based on summing percentages from the article on chemical composition of the human body. Some diversity of opinion exist about the essential nature of various ultratrace elements in humans (and other mammals), even based on the same data. For example, whether chromium is essential in humans is debated. No Cr-containing biochemical has been purified. The United States and Japan designate chromium as an essential nutrient, but the European Food Safety Authority (EFSA), representing the European Union, reviewed the question in 2014 and does not agree.
=== Reaction === Limulus clotting enzyme uses 2H2O to cleave the Arg18-Gly19 and Arg46-Thr47 linkages in coagulogen, forming coagulin + two peptide products. This process activates coagulin, allowing it to gel and form clots around bacterial invaders. The reaction is hydrolytic and catalyzed by the His-Asp-Ser triad in the active site. The hydroxyl group in serine acts as a nucleophile, attacking the carbonyl carbon in the peptide bond. Histidine’s nitrogen atom accepts the hydrogen from serine’s hydroxyl group to make serine a stronger nucleophile. Aspartic acid forms hydrogen bonds with histidine to make this nitrogen atom more electronegative and therefore more likely to accept the hydrogen. The nucleophilic attack results in the peptide bond breaking, allowing one peptide fragment to be released. A water molecule is then deprotonated by the histidine. The resulting hydroxyl acts as a nucleophile to break the bond between the serine and the carbonyl, releasing the rest of the protein. The process is then repeated at the other peptide bond.
Malaysian 7-Eleven stores are owned by 7-Eleven Malaysia Sdn. Bhd., which operates 3,225 stores nationwide. 7-Eleven in Malaysia was incorporated on June 4, 1984, as a joint venture of Jardine Matheson, Innovest and Antah Holdings group. The first 7-Eleven store was opened in October 1984, in Jalan Bukit Bintang, Kuala Lumpur. Its 2,000th outlet at Jalan Klang Lama opened in July 2016.
=== Research === In 2013, Rocky De Nys and his team at JCU along with CSIRO performed in vitro tests on 30 tropical macroalgae species using an artificial cow stomach. Dried seaweed biomass was mixed in with low quality roughage and combined with rumen fluid. Temperature and pH were then maintained to accurately simulate the fermentation process that occurs within ruminant stomachs during digestion. The total volume and concentrations of produced gases were measured for each sample at 12-hour intervals over a 72-hour period. All seaweed species were shown to reduce methane emissions in some capacity with a 50% average reduction. However this required dosages as much as 20% of dietary intake. This was problematic as the high concentrations required would most likely cause digestion issues for livestock by reducing the volume of volatile fatty acids. Asparagopsis taxiformis proved the most effective with a measured methane reduction of 98.9%. Dictyota was the second most effective seaweed with a measured methane reduction of 92%. The results of this experiment provided sufficient evidence for CSIRO to select Asparagopsis as the main ingredient in livestock feed. In 2014, a patent on a method for reducing total gas production and/or methane production in ruminants (such as sheep and cattle) was registered by CSIRO, MLA and JCU. De Nys and Kinley expanded upon the experiment in 2015 with the goal of finding an ideal dosage of Asparagopsis. The aim was to maximise methane reduction without compromising enteric health.
Since irregularities in the menstrual cycle are normal shortly after menarche and during perimenopause, the age of the individual and the time since menarche need to be taken into account. Menstrual cycles are considered irregular in the following cases:
Sources: en.wikipedia.org
It is a synthetic peptide of seven amino acids. Its backbone corresponds to a fragment of adrenocorticotropic hormone extended at the carboxyl end. The material is distributed as a lyophilized solid for laboratory use.
The extension was introduced to slow enzymatic breakdown of the peptide in biological systems. Natural ACTH fragments are degraded rapidly by peptidases. Adding the tripeptide was intended to extend the window during which the molecule remains intact.
Most published work consists of animal experiments conducted in a small number of laboratories. Human data are limited in number and size. Whether the observed effects translate into reliable clinical benefit is still unresolved.
Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.